Pancreatic Cancer Research

Clinical trialPhase 2Active not recruiting

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

Sulfonylurea Safety and Effectiveness (SUSS) for Patients With Hyperglycemia and Pancreatic Ductal Adenocarcinoma: A Pragmatic Clinical Trial and Accompanying Retrospective Revie

Outcome
Ongoing
Phase
Phase 2
Status
Active not recruiting
Study type
Interventional
Start
5 December 2023
Expected end
5 December 2026
Enrollment
29 participants
Sites
7
Primary outcomes
Change in mean interstitial glucose level for Cohort 1 participants before and after initiation of glipizide
Sponsor type
Academic / other
Results posted
No
Last update
6 August 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of this study is to find out how effective and safe glipizide is for lowering blood sugar in people with pancreatic cancer.